New eye drug dosing strategy aims to prevent blindness in High-Risk AMD patients
NCT ID NCT07187804
First seen Oct 31, 2025 · Last updated May 05, 2026 · Updated 18 times
Summary
This study tests faricimab, an eye injection, using a personalized dosing schedule for people with a specific type of wet age-related macular degeneration (type 3 MNV). The goal is to see if this approach can better preserve vision and prevent disease worsening. About 30 participants will receive injections at intervals adjusted based on their eye health, with follow-up over 76 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kim's Eye Hospital
Seoul, 150-034, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.